First, investigators used a mouse CRC model in which an inducible transgene encoding the oncogenic mutant KRASG12D and the conditional null alleles of Apc and Trp53 tumor suppressors (designated iKAP) showed that the oncogenic mutant KRAS (KRAS*) CRC had higher metastatic rates and worse outcomes in males than in females. This evidence concerns the gene KRAS and colorectal carcinoma.